Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 24, Issue 2, Pages 283-291
Publisher
Oxford University Press (OUP)
Online
2012-10-01
DOI
10.1093/annonc/mds286
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial).
- (2017) V. Guarneri et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer.
- (2017) J. C. N. Chang et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis.
- (2017) G. Bianchini et al. JOURNAL OF CLINICAL ONCOLOGY
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
- (2011) Min Ni et al. CANCER CELL
- Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women
- (2011) R. Hu et al. CLINICAL CANCER RESEARCH
- Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
- (2011) Gunter von Minckwitz et al. EUROPEAN JOURNAL OF CANCER
- Clinical Notice for American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations on ER/PgR and HER2 Testing in Breast Cancer
- (2011) M. Elizabeth Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study
- (2011) David J. Dabbs et al. JOURNAL OF CLINICAL ONCOLOGY
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- (2011) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study
- (2011) Laura C Collins et al. MODERN PATHOLOGY
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer
- (2011) Seung Il Kim et al. ONCOLOGY
- Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories
- (2010) Frederick L. Baehner et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
- (2010) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
- (2010) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastatic Behavior of Breast Cancer Subtypes
- (2010) Hagen Kennecke et al. JOURNAL OF CLINICAL ONCOLOGY
- Deconstructing the molecular portraits of breast cancer
- (2010) Aleix Prat et al. Molecular Oncology
- Expression of androgen receptors in primary breast cancer
- (2009) S. Park et al. ANNALS OF ONCOLOGY
- Time to First Tumor Progression as Outcome Predictor of a Second Trasuzumab-Based Therapy beyond Progression in HER-2 Positive Metastatic Breast Cancer
- (2009) Giulio Metro et al. Breast Journal
- Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status
- (2009) Yeon Hee Park et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
- (2009) B. T. Hennessy et al. CANCER RESEARCH
- Androgen Receptor Inhibits Estrogen Receptor- Activity and Is Prognostic in Breast Cancer
- (2009) A. A. Peters et al. CANCER RESEARCH
- Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
- (2009) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel inHER2-Positive Metastatic Breast Cancer
- (2009) Andrew M. Wardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
- (2009) Leo A Niemeier et al. MODERN PATHOLOGY
- Genes that mediate breast cancer metastasis to the brain
- (2009) Paula D. Bos et al. NATURE
- Gene-Expression Signatures in Breast Cancer
- (2009) Christos Sotiriou et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
- (2008) M. Untch et al. ANNALS OF ONCOLOGY
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- (2008) David Cameron et al. BREAST CANCER RESEARCH AND TREATMENT
- Identification of brain- and bone-specific breast cancer metastasis genes
- (2008) Andreas Klein et al. CANCER LETTERS
- A Phase II Study of Weekly Vinorelbine and Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer
- (2008) Juan Lucas Bayo-Calero et al. Clinical Breast Cancer
- A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
- (2008) C. L. Arteaga et al. CLINICAL CANCER RESEARCH
- Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)
- (2008) G. Schilling et al. INVESTIGATIONAL NEW DRUGS
- Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory
- (2008) Sunil S. Badve et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- The genomic profile ofHER2-amplified breast cancers: the influence of ER status
- (2008) C Marchiò et al. JOURNAL OF PATHOLOGY
- HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
- (2008) H Korkaya et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started